Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stojan Peric

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
European Journal of Neurology|November 17, 2025
Novel Mutations in Titin Exon 363 With Different Phenotypes Including a Founder Mutation in Eastern EuropeVeronica Sian, Maria Francesca Di Feo, Sergei Kurbatov, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|April 27, 2020
Disability and quality of life in Guillain-Barré syndrome - Longitudinal studyIvana Berisavac, Mirjana Arsenijevic, Ivo Bozovic, et al.
Journal of Neurology|November 1, 2017
Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathyIvo Bozovic, Aleksandra Kacar, Stojan Peric, et al.
Journal of the Peripheral Nervous System : JPNS|September 2, 2020
Incidence and mortality rates of Guillain-Barré syndrome in SerbiaAleksandar Stojanov, Ivana Berisavac, Ivo Bozovic, et al.
The Lancet. Neurology|June 19, 2021
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialJames F Howard, Vera Bril, Tuan Vu, et al.
Journal of the Peripheral Nervous System : JPNS|January 24, 2018
Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathyAleksandra Kacar, Bogdan Bjelica, Ivo Bozovic, et al.
Acta Myologica : Myopathies and Cardiomyopathies : Official Journal of the Mediterranean Society of Myology|December 3, 2019
Phenotypic and genetic spectrum of patients with limb-girdle muscular dystrophy type 2A from SerbiaStojan Peric, Jelena Stevanovic, Katherine Johnson, et al.
Journal of the Peripheral Nervous System : JPNS|January 14, 2015
Clinical and epidemiological features of Guillain-Barré syndrome in the Western BalkansStojan Peric, Vuk Milosevic, Ivana Berisavac, et al.
Frontiers in Neurology|February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravisJames F Howard, Vera Bril, Tuan Vu, et al.
JAMA Neurology|April 27, 2026
Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical TrialFrancesco Saccà, Gino Gialdini, James F Howard, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
European Journal of Neurology|November 17, 2025
Novel Mutations in Titin Exon 363 With Different Phenotypes Including a Founder Mutation in Eastern EuropeVeronica Sian, Maria Francesca Di Feo, Sergei Kurbatov, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|April 27, 2020
Disability and quality of life in Guillain-Barré syndrome - Longitudinal studyIvana Berisavac, Mirjana Arsenijevic, Ivo Bozovic, et al.
Journal of Neurology|November 1, 2017
Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathyIvo Bozovic, Aleksandra Kacar, Stojan Peric, et al.
Journal of the Peripheral Nervous System : JPNS|September 2, 2020
Incidence and mortality rates of Guillain-Barré syndrome in SerbiaAleksandar Stojanov, Ivana Berisavac, Ivo Bozovic, et al.
The Lancet. Neurology|June 19, 2021
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialJames F Howard, Vera Bril, Tuan Vu, et al.
Journal of the Peripheral Nervous System : JPNS|January 24, 2018
Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathyAleksandra Kacar, Bogdan Bjelica, Ivo Bozovic, et al.
Acta Myologica : Myopathies and Cardiomyopathies : Official Journal of the Mediterranean Society of Myology|December 3, 2019
Phenotypic and genetic spectrum of patients with limb-girdle muscular dystrophy type 2A from SerbiaStojan Peric, Jelena Stevanovic, Katherine Johnson, et al.
Journal of the Peripheral Nervous System : JPNS|January 14, 2015
Clinical and epidemiological features of Guillain-Barré syndrome in the Western BalkansStojan Peric, Vuk Milosevic, Ivana Berisavac, et al.
Frontiers in Neurology|February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravisJames F Howard, Vera Bril, Tuan Vu, et al.
JAMA Neurology|April 27, 2026
Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical TrialFrancesco Saccà, Gino Gialdini, James F Howard, et al.
Pageof 12